Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Bio Systems
|
January 1, 1997
Generation of fractals from incursive automata, digital diffusion and wave equation systems
D M Dubois
Proceedings of the National Academy of Sciences of the United States of America
|
May 1, 1975
Molecular model of postsynaptic potential
D M Dubois, E Schoffeniels
Proceedings of the National Academy of Sciences of the United States of America
|
July 1, 1974
A molecular model of action potentials
D M Dubois, E Schoffeniels
British Journal of Clinical Pharmacology
|
June 1, 1983
Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis
B L Flouvat, C Imbert, D M Dubois, et al.
Journal of Clinical Anesthesia
|
April 25, 2000
Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group
B K Philip, C H McLeskey, J E Chelly, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 17, 1998
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials
J B Whitmore, M G Kris, P J Hesketh, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Bio Systems
|
January 1, 1997
Generation of fractals from incursive automata, digital diffusion and wave equation systems
D M Dubois
Proceedings of the National Academy of Sciences of the United States of America
|
May 1, 1975
Molecular model of postsynaptic potential
D M Dubois, E Schoffeniels
Proceedings of the National Academy of Sciences of the United States of America
|
July 1, 1974
A molecular model of action potentials
D M Dubois, E Schoffeniels
British Journal of Clinical Pharmacology
|
June 1, 1983
Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis
B L Flouvat, C Imbert, D M Dubois, et al.
Journal of Clinical Anesthesia
|
April 25, 2000
Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group
B K Philip, C H McLeskey, J E Chelly, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 17, 1998
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials
J B Whitmore, M G Kris, P J Hesketh, et al.
Page
of 1